{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Iyer R"],"funding":["NCI NIH HHS"],"pubmed_abstract":["Synovial Sarcoma (SySa) is an aggressive soft tissue sarcoma that accounts for 5 - 10% of all soft tissue sarcomas. Current treatment involves radiation and radical surgery including limb amputation, highlighting the urgent need to develop targeted therapies. We reasoned that transcriptional rewiring by the fusion protein SS18-SSX, the sole oncogenic driver in SySa, creates specific vulnerabilities that can be exploited for treatment. To uncover genes that are selectively essential for SySa, we mined The Cancer Dependency Map (DepMap) data to identify genes that specifically impact the fitness of SySa compared to other tumor cell lines. Targeted CRISPR library screening of SySa-selective candidates revealed that the small ubiquitin-like modifier 2 (SUMO2) was one of the strongest dependenc"],"journal":["bioRxiv : the preprint server for biology"],"pagination":["2024.09.23.614593"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11463515"],"repository":["biostudies-literature"],"pubmed_title":["SUMO2 Inhibition Reverses Aberrant Epigenetic Rewiring Driven by Synovial Sarcoma Fusion Oncoproteins and Impairs Sarcomagenesis."],"pmcid":["PMC11463515"],"funding_grant_id":["R01 CA244729","R01 CA262746","P30 CA030199"],"pubmed_authors":["Kim T","Brien GL","Bala PA","Vuori K","Iyer R","Soragni A","Murad R","Pedgaonkar A","Deshpande A","Finlay D","Deshpande AJ"],"additional_accession":[]},"is_claimable":false,"name":"SUMO2 Inhibition Reverses Aberrant Epigenetic Rewiring Driven by Synovial Sarcoma Fusion Oncoproteins and Impairs Sarcomagenesis.","description":"Synovial Sarcoma (SySa) is an aggressive soft tissue sarcoma that accounts for 5 - 10% of all soft tissue sarcomas. Current treatment involves radiation and radical surgery including limb amputation, highlighting the urgent need to develop targeted therapies. We reasoned that transcriptional rewiring by the fusion protein SS18-SSX, the sole oncogenic driver in SySa, creates specific vulnerabilities that can be exploited for treatment. To uncover genes that are selectively essential for SySa, we mined The Cancer Dependency Map (DepMap) data to identify genes that specifically impact the fitness of SySa compared to other tumor cell lines. Targeted CRISPR library screening of SySa-selective candidates revealed that the small ubiquitin-like modifier 2 (SUMO2) was one of the strongest dependenc","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Sep","modification":"2026-04-08T19:16:46.521Z","creation":"2025-04-04T22:47:54.542Z"},"accession":"S-EPMC11463515","cross_references":{"pubmed":["39386552"],"doi":["10.1101/2024.09.23.614593"]}}